Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib plus AIEOP-BFM 2017 chemotherapy in pediatric acute lymphoblastic leukemia with JAK/STAT pathway activation
2020-005019-29Phase 2Active
- Sponsor
- Medical University of Lodz
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in acute lymphoblastic leukemia (ALL), sponsored by Medical University of Lodz. Primary endpoint: Proportion of patients with MRD-negative status at TP2. Started Nov 2020; status: active.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2020-005019-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005019-29.